JWJuan Wang

Juan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Juan Wang has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Guixiang Tai

    Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China

    11 shared publications
  • Fei Xie

    Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China

    8 shared publications
  • Hongyan Yuan

    Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China

    8 shared publications
  • Qiongshu Li

    Department of Immunology, College of Basic Medical Science, Jilin University, Changchun, Jilin 130021, P.R. China

    8 shared publications
  • Tanxiu Chen

    Department of Immunology, College of Basic Medical Science, Jilin University, Changchun 130021, China

    7 shared publications
  • Ruiping Zhai

    Department of Immunology, College of Basic Medical Science, Jilin University, Changchun, Jilin 130021, P.R. China

    6 shared publications

Latest Publications

  • Open Access

    Conservative treatment of giant spontaneous retropharyngeal hematoma: A case report

    by Guoqiang Du, Yao Bi, Yongtuan Li, Lingling Song, Juan Wang

    Rationale: Spontaneous retropharyngeal hematoma (SRH) is an occult disease that can cause rapid airway obstruction. Currently, no standardized diagnostic and therapeutic protocols have been established. In this case report, we present the successful conservative management of a patient with a giant SRH, further discuss strategies for airway management and hematoma evacuation, and intend to offer practical insights for the diagnosis and management of SRH. Patient concerns: A 54-year-old female patient with rapidly progressive neck swelling and respiratory tract obstruction. Diagnoses: The patient was diagnosed with SRH through computed tomography, magnetic resonance imaging, laryngoscope and ultrasound-guided aspiration biopsy. Interventions: Timely orotracheal intubation, tracheotomy, and anti-infective therapy. Outcomes: After these treatments, the patient successfully had the tracheostomy tube removed after 4 weeks and was discharged from the hospital upon recovery. Lessons: This case emphasizes the importance of early identification of SRH. It also highlights that the treatment focus for SRH lies in airway management and the selection of hematoma evacuation protocols. Furthermore, it underscores the need to consider the regularity of hematoma absorption time in the retropharyngeal space, as well as the timing and approach of surgery that should be taken into account when evacuating the hematoma.

  • P311 knockdown alleviates hyperoxia-induced injury by inactivating the Smad3 signaling pathway in type II alveolar epithelial cells

    by Jun Jiang, Juan Wang, Cen Li, Lianqin Mo, Dong Huang

    P311 is associated with alveolar formation and development. However, the role and possible mechanism of P311 in hyperoxia-induced injury in type II alveolar epithelial cells (AEC II) need to be elucidated. In our study, rat AEC II (RLE-6TN) were exposure to normoxia (21% O2 and 5% CO2) or hyperoxia (95% O2 and 5% CO2) for 24 h, followed by determination of P311 expression. After knockdown of P311 and hyperoxic treatment, cell viability, cell cycle progression, apoptosis and the Smad3 signaling pathway were examined. Rat AEC II were pretreated with SIS3 HCl for 4 h and then subjected to P311 overexpression plasmid transfection and hyperoxic exposure. Then, cell viability, apoptosis and the Smad3 signaling pathway were determined. The results showed that hyperoxic exposure significantly elevated P311 levels in rat AEC II. P311 knockdown increased cell viability, accelerated cell cycle progression and inhibited apoptosis, as well as suppression of the Smad3 signaling pathway in hyperoxia-exposed AEC II. Additionally, we found that P311 overexpression enhanced the effects of hyperoxia. Interestingly, SIS3 HCl incubation blocked the effects of P311 overexpression on rat AEC II function under hyperoxic condition, as evidenced by an increase in cell viability, and suppressions of apoptosis and the Smad3 signaling pathway. These results indicate that P311 knockdown may ameliorate hyperoxia-induced injury by inhibiting the Smad3 signaling pathway in rat AEC II. P311 may be a novel target for the treatment of hyperoxia-induced lung injury and even bronchopulmonary dysplasia (BPD).

  • MRP8/14 mediates macrophage efferocytosis through RAGE and Gas6/MFG‐E8, and induces polarization via TLR4‐dependent pathway

    by Kangxin Li, Guiming Chen, Haihua Luo, Jianhang Li, Aihua Liu, Chen Yang, Juan Wang, Jia Xu, Shenghan Gao, Peng Chen, et al.

    Myeloid‐related protein 8/14 (MRP8/14) participates in various inflammatory responses, however, its effect on macrophage efferocytosis remains unclear. Here, we demonstrate that MRP8/14 significantly inhibits the efferocytosis of apoptotic thymocytes by mouse bone marrow‐derived macrophages (BMDMs), which later proves to be associated with the receptor for advanced glycation end products (RAGE) or for reducing the expression of growth arrest‐specific protein 6 and milk fat globule epidermal growth factor 8, independent of RAGE. Furthermore, MRP8/14 promotes polarization of BMDMs from the M2‐ to M1‐like phenotype by upregulating expression of M1‐related surface receptor proteins and signature M1‐marker genes and by downregulating signature M2‐marker gene expression, which depends on Toll‐like receptor 4 and p38 mitogen‐activated protein kinase/nuclear factor κB pathways. Thus, we report a significant inhibitory effect of MRP8/14 on macrophage efferocytosis and MRP8/14‐mediated phenotypic polarization, which may be helpful in developing novel therapeutic strategies leading to inflammation resolution.


  • Open Access

    Rapamycin increases breast tumor burden in young wheel-running mice

    by Juan Wang, Thomas Truong, Warren Ladiges, Jorming Goh

    Rapamycin is an immunosuppressive and anti-cancer drug recently shown to enhance healthy aging in animal models. Regular physical exercise is associated with healthy aging and reduced risk of age-related diseases, such as cancer. In order to test the combined effect of these approaches, mice with 4T1 breast cancer were fed rapamycin at 14 ppm and allowed access to voluntary running wheels. After 17 days of treatment, mice fed the rapamycin diet that ran showed a significant increase in tumor burden compared with mice that did not run (P = 0.017). Not only does this have implications for young breast cancer patients, but suggests that combining rapamycin and exercise as an anti-aging strategy at a young age might be contraindicated.


  • Development and application of a double- antibody sandwich ELISA kit for the detection of serum MUC1 in lung cancer patients

    by Juan Wang, Shufang Zhang, Weihua Ni, Xiaoyu Zhai, Fei Xie, Hongyan Yuan, Sujun Gao, Guixiang Tai

    BACKGROUND: Mucin 1 (MUC1), as an oncogene, plays an important role in the diagnosis of lung cancer. OBJECTIVE: To establish a double-antibody sandwich enzyme-linked immune sorbent assay (ELISA) kit for the detection of serum MUC1 in lung cancer pati


  • Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development

    by Juan Wang, Guixiang Tai

    Hepatocellular carcinoma (HCC) is among the most frequently occurring cancers and the leading causes of cancer mortality worldwide. Identification of the signaling pathways regulating liver carcinogenesis is critical for developing novel chemoprevention and targeted therapies. C-Jun N-terminal kinase (JNK) is a member of a larger group of serine/threonine (Ser/Thr) protein kinases known as the mitogen-activated protein kinase (MAPK) family. JNK is an important signaling component that converts external stimuli into a wide range of cellular responses, including cell proliferation, differentiation, survival, migration, invasion, and apoptosis, as well as the development of inflammation, fibrosis, cancer growth, and metabolic diseases. Because of the essential roles of JNK in these cellular functions, deregulated JNK is often found to contribute to the development of HCC. Recently, the functions and molecular mechanisms of JNK in HCC development have been addressed using mouse models and human HCC cell lines. Furthermore, recent studies demonstrate that the activation of JNK by oncogenes can promote the development of cancers by regulating the transforming growth factor (TGF)-beta/Smad pathway, which makes the oncogenes/JNK/Smad signaling pathway an attractive target for cancer therapy. Additionally, JNK-targeted therapy has a broad potential for clinical applications. In summary, we are convinced that promising new avenues for the treatment of HCC by targeting JNK are on the horizon, which will undoubtedly lead to better, more effective, and faster therapies in the years to come.


  • Pre-clinical toxicity and immunogenicity evaluation of a MUC1–MBP/BCG anti-tumor vaccine

    by Boqi Hu, Juan Wang, Yingying Guo, Tanxiu Chen, Weihua Ni, Hongyan Yuan, Nannan Zhang, Fei Xie, Guixiang Tai


  • Open Access

    Mucin 1 gene silencing inhibits the growth of SMMC-7721 human hepatoma cells through Bax-mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways

    by Hongyan Yuan, Juan Wang, Fengli Wang, Nannan Zhang, Qiongshu Li, Fei Xie, Tanxiu Chen, Ruiping Zhai, Fang Wang, Yingying Guo, et al.

    Mucin 1 (MUC1) is an oncogene that has a crucial role in the pathogenesis and progression of the majority of epithelial malignant tumors. Our previous study demonstrated that MUC1 gene silencing inhibited the growth of SMMC‑7721 cells in vitro and in vivo, however, whether this growth inhibition is associated with apoptotic cell death remains to be elucidated. In the present study, it was found that MUC1 gene silencing not only resulted in the inhibition of SMMC‑7721 cell growth, determined using a clone formation assay in vitro and a tumor xenograft mouse model with an in vivo imaging system, but also induced apoptotic alterations in SMMC‑7721 cells, determined using Hoechst 33342 staining, flow cytometry with an Annexin V-PE staining and a DNA ladder assay. Further investigation using western blotting revealed that cytochrome c was released from the mitochondria into the cytoplasm, and caspase‑8 and caspase‑9 were activated in MUC1 gene‑silenced SMMC‑7721 cells. The pro‑apoptotic protein Bcl‑2‑associated X protein (Bax) and the tumor suppressor p53 were increased, while the anti‑apoptotic protein B‑cell lymphoma 2 was decreased in MUC1 gene‑silenced cells. In addition, results from the co‑immunoprecipitation experiments demonstrated that the MUC1 cytoplasmic tail can bind directly to Bax or caspase‑8 and these interactions were reduced upon MUC1 gene silencing in SMMC‑7721 cells. The above results indicate that MUC1 gene silencing induces growth inhibition in SMMC‑7721 cells through Bax‑mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways.


  • Escherichia coli maltose-binding protein (MBP) directly induces mouse Th1 activation through upregulating TLR2 and downregulating TLR4 expressions

    by Fang Wang, Weihua Ni, Guomu Liu, Juan Wang, Fei Xie, Hongyan Yuan, Yingying Guo, RuiPing Zhai, Tanxiu Chen, Qiongshu Li, et al.